한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

in 2023, nouva health is facing a huge crisis. capitalwatch released an investigation report, revealing that nouva health created false sales revenue by continuously hoarding goods, triggering a serious financial fraud storm. nouva health clarified the matter, but its attitude made investors feel uneasy. with the intervention of the capital market and regulatory agencies, the fate of nouva health will also be put to a huge test.

faced with public pressure and regulatory scrutiny, nouva health had to issue a statement claiming that its financial information was true and accurate. however, deloitte's letter of concern and report made things more complicated. in 2024, nouva health encountered major challenges, from the suspension of trading to the establishment of an independent special committee, with ups and downs along the way.

under heavy pressure, nouva health finally issued an announcement and appointed two independent non-executive directors to form an independent special committee including two new directors to investigate the matter. behind this is the market's doubts about nouva health and the regulatory authorities' attention to financial fraud.

as time goes by, nouva health finally faces the test of the resumption of trading guidance. in september 2024, nouva health was removed from the list of securities subject to the "hong kong stock connect". however, all this is not over yet. nouva health has experienced a huge crisis and has also undergone tremendous changes. it needs to rebuild its reputation and credibility.